

6. Do you have a history of any immediate allergic reactions of any severity* (definition below) Yes No
to any vaccines OR to injectable therapy (i.e., intramuscular, intravenous or subcutaneous)?

IF YES, IT IS OKAY TO VACCINATE AS LONG AS INDIVIDUAL DOES NOT HAVE A CONTRAINDICATION TO VACCINATION (SEE QUESTION 5) AND HAS SPOKEN WITH HIS/HER PROVIDER OR A RESOURCE NURSE/LICENSED INDEPENDENT PRACTITIONER (LIP) AT VACCINE SITE AND UNDERSTANDS THERE IS AN ELEVATED RISK OF ALLERGIC REACTION. IF INDIVIDUAL HAS NOT SPOKEN WITH HIS/HER PROVIDER, THEN INDIVIDUAL IS REQUIRED TO SPEAK WITH VACCINE SITE RESOURCE NURSE/LIP AS AN ALTERNATIVE FOR PURPOSES OF RISK ASSESSMENT. SEE VACCINE RECIPIENT INFORMATION REGARDING DETAILS ON RISK ASSESSMENT. IF THE ALLERGY IS TO AN mRNA COVID-19 VACCINE AND INDIVIDUAL IS RECEIVING J&J VACCINE OR VICE VERSA, CDC RECOMMENDS THAT THE INDIVIDUAL CONSULT WITH AN ALLERGIST PRIOR TO VACCINATION. IT WOULD BE UP TO THE INDIVIDUAL TO DECIDE TO PURSUE THIS OPTION. (FOR MORE DETAILS SEE QUESTION #5.)

INDIVIDUAL REQUIRES 30-MINUTE WAITING PERIOD.

7. Do you have a history of anaphylaxis due to any other cause Yes No
not already mentioned (i.e., not related to COVID-19 vaccines, or to vaccines or injectables)?

Examples include but are not limited to: food allergies, oral medication, insect, venom, latex, etc.

IF YES, IT IS OKAY TO VACCINATE.

INDIVIDUAL REQUIRES 30-MINUTE WAITING PERIOD.

8. Do you have a bleeding disorder or are you taking blood thinners? Yes No

IF YES, IT IS OKAY TO VACCINATE BUT USE FINE GAUGE NEEDLE (23- OR 25-GAUGE)

AND APPLY PRESSURE TO VACCINATION SITE FOR 2 MINUTES.

_____ **EUA or VIS provided on this date**

_____ **Vaccinator Printed Name and Signature and Date**

**Immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria (hives), angioedema (swelling), respiratory distress such as shortness of breath, wheezing, stridor or anaphylaxis that occur within four hours following administration*

Pfizer vaccine components are:

COVID-19 mRNA Vaccine BNT 162b2 concentrate for solution for injection
ALC-0315 = (4-hydroxybutyl) azanediyl)bis (hexane-6,1-diy1)bis(2-hexyldecanoate),
ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide,
1,2-Distearoyl-sn-glycero-3-phosphocholine, cholesterol,
potassium chloride,
potassium dihydrogen phosphate,
sodium chloride,
disodium hydrogen phosphate dihydrate, sucrose,
water for injections

Moderna vaccine components are:

COVID-19 Vaccine contains 100 mcg of nucleoside- modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
Each dose of the Moderna COVID-19 Vaccine contains the following ingredients: a total lipid content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), 0.31 mg tromethamine, 1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid, 0.12 mg sodium acetate, and 43.5 mg sucrose.

Janssen (Johnson & Johnson) vaccine components are:

Each 0.5 mL dose of Janssen COVID-19 Vaccine is formulated to contain 5×10^{10} virus particles (VP) and the following inactive ingredients: citric acid monohydrate (0.14 mg), trisodium citrate dihydrate (2.02 mg), ethanol (2.04 mg), 2-hydroxypropyl- β -cyclodextrin (HBCD) (25.50 mg), polysorbate-80 (0.16 mg), sodium chloride (2.19 mg). Each dose may also contain residual amounts of host cell proteins (≤ 0.15 mcg) and/or host cell DNA (≤ 3 ng).